Neutral fat absorption inhibitor, food product, and medicine

Abstract

To provide: a neutral fat absorption inhibitor excellent in absorption inhibition effect of neutral fat; and a food product and a medicine which include the neutral fat absorption inhibitor.SOLUTION: A neutral fat absorption inhibitor includes calcium alginate, and 90th percentile value (D90) of a grain size distribution of the calcium alginate is less than 53 μm.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a neutral fat absorption inhibitor for inhibiting the absorption of neutral fats in humans or animals, and to a food and a medicine containing the neutral fat absorption inhibitor. [Background technology]

[0002] Alginic acid is a natural polysaccharide found in brown algae such as kelp and wakame seaweed. Alginic acid, alginates, and their derivatives are used as thickeners, stabilizers, gelling agents, etc. in the food industry, and are also used in a wide range of other applications, including pharmaceuticals, cosmetics, and textile processing.

[0003] Alginic acid is a type of dietary fiber, and among alginates, sodium alginate, for example, is known to have the effect of lowering blood cholesterol and improving bowel movements.

[0004] Among alginates, calcium alginate has also been widely studied. For example, Non-Patent Document 1 shows the effect of calcium alginate in inhibiting the absorption of neutral fat in rats. However, Non-Patent Document 1 does not verify the particle size of calcium alginate. Furthermore, Patent Document 1 shows an invention related to healthy boiled noodles with a high texture that utilizes the health benefits of calcium alginate. However, Patent Document 1 does not cite the effect of inhibiting the absorption of neutral fat as a specific health benefit. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Patent No. 6934073 [Non-patent literature]

[0006] [Non-Patent Document 1] Fumiyoshi Kasahara, Takako Kato, Yoko Idota, Hitoe Takahashi, Chihaya Kakinuma, Kentaro Yano, Hiroshi Arakawa, Kurt Hara, Chihiro Miyajima, Takuo Ogihara, Reduction Effect of Calcium Alginate on Blood Triglyceride Levels Causing the Inhibition of Hepatic and Total Body Accumulation of Fat in Rats, Biological and Pharmaceutical Bulletin, 2019, Volume 42, Issue 3, p. 365-372 Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide a neutral fat absorption inhibitor having an excellent neutral fat absorption inhibitory effect, and a food and a medicine containing the neutral fat absorption inhibitor. [Means for solving the problem]

[0008] The present invention is a neutral fat absorption inhibitor comprising calcium alginate, the calcium alginate having a 90th percentile value (D90) of particle size distribution of less than 53 μm.

[0009] In the neutral fat absorption inhibitor, the neutral fat is preferably a triglyceride.

[0010] The present invention is a food product comprising the neutral fat absorption inhibitor.

[0011] The present invention is a pharmaceutical comprising the neutral fat absorption inhibitor. Effect of the Invention

[0012] According to the present invention, it is possible to provide a neutral fat absorption inhibitor having an excellent neutral fat absorption inhibitory effect, and a food and a medicine containing the neutral fat absorption inhibitor. [Brief description of the drawings]

[0013] [Figure 1] 1 is a graph showing the change over time in blood neutral fat concentration when calcium alginate having different particle sizes was given to rats. [Diagram 2] 1 is a graph showing the change over time in blood neutral fat concentration when a capsule filled with calcium alginate was given to rats. [Diagram 3] 1 is a graph showing the change over time in blood neutral fat concentration when calcium alginate was kneaded into udon noodles and given to rats. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The following describes an embodiment of the present invention. The embodiment is merely an example of implementing the present invention, and the present invention is not limited to the embodiment.

[0015] <Neutral fat absorption inhibitor> The neutral fat absorption inhibitor according to this embodiment contains calcium alginate, and the 90th percentile value (D90) of the particle size distribution of calcium alginate is less than 53 μm.

[0016] As a result of the intensive research of the present inventors, it was found that calcium alginate (Ca-Alg), especially fine particles, has a remarkably high neutral fat absorption inhibitory effect. The present inventors found that the particle size of calcium alginate is involved in the neutral fat absorption inhibitory effect, and that calcium alginate with a 90th percentile value (D90) of particle size distribution of less than 53 μm, that is, calcium alginate powder with 90% or more of the powder particles having a diameter of less than 53 μm, can fully bring out the neutral fat absorption inhibitory effect. In addition, it was found that calcium alginate with a 90th percentile value (D90) of particle size distribution of less than 53 μm can inhibit the absorption of ingested neutral fat and inhibit the increase of neutral fat concentration in blood.

[0017] Alginic acid is a biodegradable polymeric polysaccharide, which is a polymer formed by linear polymerization of two types of uronic acid, D-mannuronic acid (M) and L-guluronic acid (G). More specifically, it is a block copolymer in which a homopolymer fraction of D-mannuronic acid (MM fraction), a homopolymer fraction of L-guluronic acid (GG fraction), and a fraction in which D-mannuronic acid and L-guluronic acid are randomly arranged (MG fraction) are arbitrarily bonded. The composition ratio (M / G ratio) of D-mannuronic acid and L-guluronic acid in alginic acid varies mainly depending on the type of organism from which seaweed and the like are derived. There is no particular limit to the M / G ratio of calcium alginate used in this embodiment.

[0018] Calcium alginate, whether low molecular weight or high molecular weight, is a water-insoluble salt and therefore shows almost no viscosity even when placed in water. The viscosity of the calcium alginate used in this embodiment when converted to sodium alginate by ion exchange reaction is not particularly limited, but it may contain one having a 10% aqueous solution viscosity of 60 mPa·s or more. More preferably, one having a 10% aqueous solution viscosity of 1000 mPa·s or more, and more preferably, one having a 1% aqueous solution viscosity of 100 mPa·s or more can be used.

[0019] In the neutral fat absorption inhibitor according to this embodiment, the particle size of calcium alginate is preferably such that the 90th percentile value (D90) of the particle size distribution measured by a laser diffraction / scattering particle size distribution measuring device is less than 53 μm. If the D90 of the particle size distribution of calcium alginate powder is 53 μm or more, the neutral fat absorption inhibitory effect is reduced.

[0020] Examples of neutral fats the absorption of which is inhibited include monoglycerides, diglycerides, and triglycerides, with triglycerides being preferred in terms of their form in the body.

[0021] The neutral fat absorption inhibitor of this embodiment may be taken once or continuously.For example, the effective intake amount of the calcium alginate is 15mg / kg or more, preferably 25mg / kg or more, and it is enough for humans or animals to take it once or more per day for at least one day.The upper limit of the effective intake amount of calcium alginate is not particularly limited, but is, for example, 3.6g / kg or less.

[0022] The neutral fat absorption inhibitor according to the present embodiment may contain, in addition to the calcium alginate, other ingredients such as food additives, pharmaceutical additives, food materials, pharmaceutical ingredients, etc. When other ingredients are contained, the amount of the other ingredients added may be appropriately determined according to the purpose of the other ingredients, within a range that does not impair the effect of the calcium alginate.

[0023] <Food> The neutral fat absorption inhibitor according to this embodiment may be a food product containing the above calcium alginate as an active ingredient.

[0024] The food according to this embodiment is a food containing a neutral fat absorption inhibitor that contains calcium alginate, in which the 90th percentile value (D90) of the particle size distribution of calcium alginate is less than 53 μm.

[0025] Here, the "food" is not particularly limited, but examples include noodles, breads, beverages, baked goods, frozen desserts, tablet sweets, candies, gummies, jellies, caramels, jams, chocolates, gums, Japanese sweets, soups, breads, various retort foods, side dishes, seafood paste products, hams, sausages, seasonings, supplements, etc. Furthermore, the "food" may be feed for livestock such as chickens, cattle, and pigs, and for fish farming.

[0026] The blending ratio of the calcium alginate in the food is not particularly limited as long as it does not affect the main purpose of each food, and a wide range of use forms may be selected according to the product form. For example, the blending ratio per solid content of the food may be about 0.01 to 100 mass%. The calcium alginate may be powdered as it is or tableted to form the food according to the present embodiment, and it can be a more natural food without additives.

[0027] When the neutral fat absorption inhibitor according to the present embodiment is used for food, the neutral fat absorption inhibitor may contain other components such as food materials and food additives, in addition to the calcium alginate, to the extent that they do not affect the main purpose of each food. When food additives are contained, the content of the food additives may be within the range of the use standard set in the Food Sanitation Law, for example.

[0028] The food according to this embodiment is intended to inhibit the absorption of neutral fats, contains the above-mentioned calcium alginate as an active ingredient, and is used to inhibit the absorption of neutral fats in humans or animals.

[0029] <Drugs> The neutral fat absorption inhibitor according to this embodiment may be a medicine containing the above calcium alginate as an active ingredient.

[0030] The pharmaceutical product according to this embodiment is a pharmaceutical product containing a neutral fat absorption inhibitor that contains calcium alginate, and in which the 90th percentile value (D90) of the particle size distribution of calcium alginate is less than 53 μm.

[0031] Here, the term "pharmaceuticals" is not particularly limited, but includes, for example, medical drugs that contain the above-mentioned calcium alginate and can be ingested, health foods developed for medical use, and veterinary drugs developed for animals other than humans.

[0032] The neutral fat absorption inhibitor according to the present embodiment may be a pharmaceutical composition containing a known medicamentically or pharma- ceutical acceptable carrier, excipient, or other additive. The pharmaceutical composition may be used to prepare medicines such as tablets, powders, fine granules, capsules, pills, granules, sustained-release preparations, oral jellies, and oral liquids. The pharmaceutical composition may also contain auxiliary pharmaceutical additives such as known stabilizers, thickeners, bulking agents, colorants, and fragrances. The content of the pharmaceutical additive when it contains a pharmaceutical additive may be, for example, within the range of the usage standard of the pharmaceutical additive.

[0033] The pharmaceutical product according to this embodiment is intended to inhibit the absorption of neutral fats, contains the above-mentioned calcium alginate as an active ingredient, and is used to inhibit the absorption of neutral fats in humans or animals. EXAMPLES

[0034] EXAMPLES The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to the following examples.

[0035] <Example 1> [Study on particle size of calcium alginate] Corn oil containing triglyceride (TG) as a neutral fat was added to a 5% by mass aqueous solution of gum arabic, and the resulting emulsion and calcium alginate (Ca-Alg) of different particle sizes were added and given to rats. Blood was then collected over time to measure the TG concentration in the blood. The amount of TG given was 500 mg / kg based on the rat's body weight. The amount of calcium alginate given was 25 mg / kg based on the rat's body weight. The maximum change in blood neutral fat concentration (blood TG concentration) (ΔCmax ) and the area under the blood concentration-time curve (ΔAUC) were used as indexes of evaluation. Three types of calcium alginate with different particle sizes were used. A list of the calcium alginates used is shown in Table 1. The time course of change in blood TG concentration is shown in Figure 1. The values ​​of the kinetic parameters used in the evaluation are shown in Table 2.

[0036] The particle size distribution of calcium alginate of 270 mesh (90th percentile value (D90) of particle size distribution is less than 53μm) was measured using a laser diffraction / scattering particle size distribution analyzer (Microtrack Bell, MT3300). The dispersion method during the measurement was wet dispersion, and methanol (refractive index 1.33) was used as the dispersion medium. It was confirmed that the 90th percentile value (D90) of the measured particle size distribution was less than 53μm. The particle sizes of 150 mesh and 80 mesh products were measured by placing the measurement sample, the weight of which was measured in advance, on a JIS standard sieve of each mesh and shaking it for 10 minutes with a low-tap sieve shaker (Tanaka Tech, R-1). In the case of the 150 mesh product, it was confirmed that the powder passing through the 150 mesh sieve (106μm mesh) was 90% or more of the test sample weight. In the case of 80 mesh products, it was confirmed that the powder passing through an 80 mesh sieve (180 μm opening) was 90% or more of the test sample weight. The opening of the sieve complies with JIS Z8801-1:2019.

[0037] [Table 1]

[0038] [Table 2]

[0039] The meanings of the kinetic parameters in Table 2 are as follows: ΔC n : Blood TG concentration (mg / dL) n hours after administration of calcium alginate ΔC max: Maximum change in blood TG concentration (mg / dL) T max : Time elapsed until blood TG concentration reached its maximum (hr) ΔAUC: Area under the blood concentration-time curve (mg·hr / dL)

[0040] The results of the test showed that in the group that ingested the 270 mesh product (the 90th percentile value (D90) of the particle size distribution is less than 53 μm), the blood TG concentration was ΔC max It was confirmed that both AUC and ΔAUC were significantly lower than in the control group (a group that ingested only emulsified neutral fat and did not ingest calcium alginate).

[0041] <Example 2> [Effect of suppressing neutral fat absorption when using capsules filled with calcium alginate] Corn oil containing triglyceride as neutral fat was added to a 5% by mass aqueous solution of gum arabic, and the resulting emulsion was given to rats. After that, capsules filled with different weights of calcium alginate (270 mesh product) were given to the rats. Blood was then collected over time to measure the TG concentration in the blood. The amount of TG given was 500 mg / kg based on the rat's body weight. The amount of calcium alginate given was 15 mg / kg, 25 mg / kg, or 40 mg / kg based on the rat's body weight. ΔC max and ΔAUC were used as the indices of evaluation. The time course of changes in blood TG concentration is shown in Figure 2. The values ​​of each kinetic parameter under each condition are shown in Table 3.

[0042] [Table 3]

[0043] The test results confirmed that both ΔCmax and ΔAUC were significantly lower in the groups that ingested 25 mg / kg or 40 mg / kg calcium alginate compared to the control group (a group that ingested only emulsified neutral fat, and no calcium alginate).

[0044] <Example 3> [Effect of calcium alginate kneaded into udon noodles on the inhibition of neutral fat absorption] Corn oil containing triglyceride as neutral fat was added to a 5% by mass aqueous solution of gum arabic to prepare a neutral fat emulsion. Different amounts of calcium alginate (270 mesh) were added to make udon noodles, which were then boiled and mixed with water to prepare homogenized noodles. The homogenized udon noodles were mixed with the neutral fat emulsion and given to rats. Blood was then collected over time to measure the TG concentration in the blood. The amount of TG given was 500 mg / kg based on the rat's body weight. The amount of calcium alginate given was 15 mg / kg, 25 mg / kg, or 40 mg / kg based on the rat's body weight. The maximum change in blood TG concentration (ΔC max The evaluation indices were the area under the blood concentration-time curve (ΔAUC) and the blood TG concentration-time curve (ΔAUC). The time course of changes in blood TG concentration is shown in Figure 3. The values ​​of each kinetic parameter under each condition are shown in Table 4.

[0045] [Table 4]

[0046] As a result of the test, in the groups that ingested calcium alginate at 15 mg / kg, 25 mg / kg, or 40 mg / kg, ΔC max It was confirmed that ΔAUC was significantly lower in the groups that received 25 mg / kg or 40 mg / kg calcium alginate compared to the control.

[0047] Thus, the neutral fat absorption inhibitors of the Examples were excellent in the neutral fat absorption inhibitory effect.

Claims

1. A neutral fat absorption inhibitor comprising calcium alginate, the calcium alginate having a 90th percentile value (D90) of particle size distribution of less than 53 μm.

2. The neutral fat absorption inhibitor according to claim 1, A neutral fat absorption inhibitor, wherein the neutral fat is a triglyceride.

3. A food comprising the neutral fat absorption inhibitor according to claim 1 or 2.

4. A pharmaceutical comprising the neutral fat absorption inhibitor according to claim 1 or 2.

Images